Company / Cash & Equivalents
Biohaven Ltd. Cash & Equivalents History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$99.1M
FY2024
5-year range
$76.1M / $248.4M
FY2020-FY2024
Trend
-60.1%
vs FY2023
Sector context
#141 of 207
Health Care
What the data says
At $99M, Biohaven Ltd.'s cash & equivalents ranks #141 of 207 in the Health Care sector. Declined from $205M to $99M over the past 2 years.
Based on SEC 10-K filings.
$99M in FY2024 with a 3-year CAGR of +9.2%.
Declined from $205M to $99M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +9.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#141 of 207 in Health CareTop 68% of 207This company $99.1M Sector average $669.5M
▼
-85.2% below sector average
Key checks
Key Insights
- 3-year CAGR of +9.2%, indicating consistent growth.
- In FY2024, cash & equivalents decreased 60.1% year-over-year.
- Ranks #141 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $99.1M | -60.1% |
| FY2023 | $248.4M | +21.2% |
| FY2022 | $204.9M | +169.4% |
| FY2021 | $76.1M | -7.8% |
| FY2020 | $82.5M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026